U.S. patent application number 11/485692 was filed with the patent office on 2006-11-02 for use of a peptide.
Invention is credited to Suad Efendic, Mark Gutniak, Ole Kirk.
Application Number | 20060247174 11/485692 |
Document ID | / |
Family ID | 8092676 |
Filed Date | 2006-11-02 |
United States Patent
Application |
20060247174 |
Kind Code |
A1 |
Efendic; Suad ; et
al. |
November 2, 2006 |
Use of a peptide
Abstract
The invention employs GLP-1 (7-37), GLP-1(7-36)amide, and
certain related compounds in combination with an oral hypoglycaemic
agent for treating diabetes mellitus.
Inventors: |
Efendic; Suad; (Lindingo,
SE) ; Gutniak; Mark; (Hasselby, SE) ; Kirk;
Ole; (Virum, DK) |
Correspondence
Address: |
NOVO NORDISK, INC.;PATENT DEPARTMENT
100 COLLEGE ROAD WEST
PRINCETON
NJ
08540
US
|
Family ID: |
8092676 |
Appl. No.: |
11/485692 |
Filed: |
July 13, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10228369 |
Aug 22, 2002 |
|
|
|
11485692 |
Jul 13, 2006 |
|
|
|
09754723 |
Jan 4, 2001 |
|
|
|
10228369 |
Aug 22, 2002 |
|
|
|
08842121 |
Apr 23, 1997 |
|
|
|
09754723 |
Jan 4, 2001 |
|
|
|
08295913 |
Oct 13, 1994 |
5631224 |
|
|
PCT/DK93/00099 |
Mar 18, 1993 |
|
|
|
08842121 |
Apr 23, 1997 |
|
|
|
Current U.S.
Class: |
514/7.2 ;
514/11.7; 514/317; 514/592 |
Current CPC
Class: |
A61K 38/26 20130101;
A61K 38/26 20130101; A61K 31/445 20130101; A61K 2300/00 20130101;
A61K 31/155 20130101; A61K 2300/00 20130101; A61K 31/64 20130101;
A61K 2300/00 20130101; A61K 38/26 20130101; A61P 3/08 20180101;
A61K 31/175 20130101; A61P 3/10 20180101; A61K 38/26 20130101; A61K
31/445 20130101; A61K 31/175 20130101 |
Class at
Publication: |
514/012 ;
514/317; 514/592 |
International
Class: |
A61K 38/36 20060101
A61K038/36; A61K 31/445 20060101 A61K031/445; A61K 31/175 20060101
A61K031/175 |
Foreign Application Data
Date |
Code |
Application Number |
Mar 19, 1992 |
DK |
0363/92 |
Claims
1. A method for treating type 2 diabetes, said method comprising
administering to a patient in need of said treatment an effective
amount of an oral hypoglycemic agent which acts on the
ATP-dependent potassium channel of beta cells and an effective
amount of a an insulinotropic GLP-1 related peptide, where said
insulinotropic GLP-1 related peptide is GLP-1 (7-37), GLP-1 (7-36)
amide, an analogue of GLP-1 (7-37) or GLP-1 (7-36) amide, or a
functional derivative thereof of any of the foregoing.
2. The method of claim 1, wherein said insulinotronic GLP-1 related
peptide is GLP-1 (7-36) amide.
3. The method of claim 1, wherein said insulinotropic GLP-1 related
peptide is an analogue of GLP-1 (7-37).
4. The method of claim 3, wherein said analogue of GLP-1 (7-37) has
one amino acid of GLP-1 (7-37) exchanged by another amino acid.
5. The method of claim 1, wherein said insulinotropic GLP-1 related
peptide is a functional derivative of an analogue of GLP-1
(7-37).
6. The method of claim 5, wherein said analogue of GLP-1 (7-37) has
one amino acid of GLP-1(7-37) exchanged by another amino acid.
7. The method of claim 1, wherein said oral hypoglycemic agent is a
sulfonylurea.
8. The method of claim 7, wherein the sulfonylurea is selected from
the group consisting of tolbutamide, glibenclamide, glipizide and
gliclazide.
9. The method of claim 1, wherein said oral hypoglycemic agent is
(S)-(+)-2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]-amino]-
-2-oxoethyl]benzoic acid.
Description
CROSS REFERENCE TO RELATED APPLICATIONS:
[0001] This application is a continuation of U.S. application Ser.
No. 10/228,369 filed on Aug. 22, 2002, which is a continuation of
Ser. No. 09/754,723 filed on Jan. 4, 2001, now abandoned, which is
a continuation of Ser. No. 08/295,913 filed on Oct. 13, 1994, that
issued as U.S. Pat. No. 5,631,224 on Oct. 28, 1998 and reissued as
reissue patent RE 37,302 on Jul. 31, 2001, which is a national
application under 35 U.S.C. 371 of PCT/DK93/00099 filed on Mar. 18,
1993, which claims priority to Danish application 363/92 filed Mar.
19, 1992, the contents of each of which are fully incorporated
herein by reference.
FIELD OF THE INVENTION
[0002] The present invention relates to the use of GLP-1(7-37),
GLP-1(7-36)amide, or certain related compounds for the preparation
of a medicament for use in the treatment of diabetes in a regimen
which additionally comprises treatment with an oral hypoglycaemic
agent. The invention also relates to a method of treating diabetes
by using said medicament.
BACKGROUND OF THE INVENTION
[0003] Diabetes is characterized by an impaired glucose metabolism
manifesting itself among other things by an elevated blood glucose
level in the diabetic patients. Underlying defects lead to a
classification of diabetes into two major groups: type 1 diabetes,
or insulin demanding diabetes mellitus (IDDM), which arises when
patients lack .beta.-cells producing insulin in their pancreatic
glands, and type 2 diabetes, or non-insulin dependent diabetes
mellitus (NIDDM), which occurs in patients with an impaired
.beta.-cell function besides a range of other abnormalities.
[0004] Type 1 diabetic patients are currently treated with insulin,
while the majority of type 2 diabetic patients are treated either
with agents that stimulate .beta.-cell function or with agents that
enhance the tissue sensitivity of the patients towards insulin.
[0005] Among the agents applied for stimulation of the .beta.-cell
function, those acting on the ATP-dependent potassium channel of
.beta.-cells are most widely used in current therapy. The so-called
sulfonylureas such as tolbutamide, glibenclamide, glipizide, and
gliclazide are used extensively and other agents such as AG-EE 623
ZW also acting at this molecular site are under development (AG-EE
623 ZW is a company code for
(S)-(+)-2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]-amino]-
-2-oxoethyl]benzoic acid, a compound described in European patent
publication No. 147,850 (to Dr. Karl Thomae GmbH)). Among the
agents applied to enhance tissue sensitivity towards insulin
metformin is a representative example.
[0006] Even though sulfonylureas are widely used in the treatment
of NIDDM this therapy is, in most instances, not satisfactory: In a
large number of NIDDM patients sulfonylureas do not suffice to
normalize blood sugar levels and the patients are, therefore, at
high risk for acquiring diabetic complications. Also, many patients
gradually lose the ability to respond to treatment with
sulfonylureas and are thus gradually forced into insulin treatment.
This shift of patients from oral hypoglycaemic agents to insulin
therapy is usually ascribed to exhaustion of the .beta.-cells in
NIDDM patients.
[0007] Over the years, numerous attempts have therefore been made
to provide novel agents which stimulate .beta.-cell function in
order to offer the NIDDM patients an improved treatment. Recently,
a series of peptides derived from glucagon-like peptide-1 have been
considered as insulinotropic agents for therapeutic use.
[0008] Glucagon-like peptide-1, also referred to as GLP-1, is a
peptide sequence found in the C-terminal portion of mammalian
proglucagon. Prior to 1985, no definite biological activity of
GLP-1 had been reported. However, in 1985 it was demonstrated that
the amide of a fragment of GLP-1, namely GLP-1(1-36)amide,
stimulates insulin release from isolated precultured rat pancreatic
islets in the presence of glucose in a dose-dependent manner
(Schmidt, W. E. et al. Diabetologia 28 (1985) 704-7). This finding
suggests that GLP-1(1-36)amide and related peptides might be useful
in the treatment of type 2 diabetes. Due to its substantially
closer sequence homology to glucagon and glucosedependent
insulinotropic peptide, also referred to as GIP, Schmidt et al.
suggested that an even stronger glucagon- and/or GIP-like
biological activity could be expected with GLP-1(7-36) than with
the intact peptide. In recent years, particular interest has
focused on the GLP-1 fragments GLP-1(7-37) and GLP-1(7-36) amide
and analogues and functional derivatives thereof. The designation
GLP-1(1-36) indicates that the peptide fragment in question
comprises the amino acid residues from (and including) number 1 to
(and including) number 36 when counted from the N-terminal end of
the parent peptide, GLP-1. Similarly, the designation GLP-1(7-37)
designates that the fragment in question comprises the amino acid
residues from (and including) number 7 to (and including) number 37
when counted from the N-terminal end of the parent peptide, GLP-1.
The amino acid sequence of GLP-1(7-36)amide and of GLP-1(7-37) is
given in formula I: TABLE-US-00001
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-
Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-
Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-X (I)
which shows GLP-1(7-36)amide when X is NH.sub.2 and GLP-1(7-37)
when X is Gly-OH.
[0009] That GLP-1(7-36)amide is indeed an insulinotropic agent in
man has been demonstrated by Kreymann, B. et al. who infused this
peptide into healthy volunteers and observed a significant rise in
plasma insulin (Lancet 2 (1987) 1300-304).
[0010] The insulinotropic action of GLP-1(7-37) in diabetic as well
as in nondiabetic subjects has been demonstrated by Nathan, D. M.
et al. Diabetes Care 15 (1992) 270-76.
[0011] International Patent Application No. WO 87/06941 (to The
General Hospital Corporation) relates to a peptide fragment which
comprises GLP-1(7-37) and functional derivatives thereof and to its
use as an insulinotropic agent.
[0012] International Patent Application No. 90/11296 (to The
General Hospital Corporation) relates to a peptide fragment which
comprises GLP-1(7-36) and functional derivatives thereof and has an
insulinotropic activity which exceeds the insulinotropic activity
of GLP-1(1-36) or GLP-1 (1-37) and to its use as an insulinotropic
agent.
[0013] International Patent Application No. 91/11457 (to Buckley et
al.) relates to effective analogs of the active GLP-1 peptides
7-34, 7-35, 7-36, and 7-37.
[0014] The effect of GLP-1(7-37) in combination with glibenclamide
on insulin secretion from rat pancreatic islets was studied in
vitro by Parker, J. C. et al. (Diabetes 40 (suppl. 1) (1991) 237
A). Only an additive effect of the two agents was observed.
[0015] However, to the best of the knowledge of the present
inventors the surprising synergistic effect in vivo achieved by the
combined use of an oral hypoglycaemic agent and a fragment of GLP-1
or an analogue or a functional derivative thereof has not
previously been disclosed.
SUMMARY OF THE INVENTION
[0016] The present invention relates to the surprising finding that
when GLP-1 related peptides are administered in combination with
oral hypoglycaemic agents in general and with sulfonylureas in
particular for treatment of type 2 diabetes, a synergistic effect
is observed. This surprising observation has been made even in type
2 diabetic patients who fail to respond when sulfonylureas are
administered alone.
[0017] Thus, in its broadest aspect the present invention relates
to the use of GLP-1(7-37), GLP-1(7-36)amide, or a pharmaceutically
acceptable peptide containing a fragment of the GLP-1(7-37)
sequence, or an analogue or a functional derivative of such a
peptide for the preparation of a medicament for use in the
treatment of type 2 diabetes in a regimen which additionally
comprises treatment with an oral hypoglycaemic agent and to a
method of treating type 2 diabetes which method comprises
administering an effective amount of GLP-1(7-37), GLP-1(7-36)amide,
or a pharmaceutically acceptable peptide containing a fragment of
the GLP-1(7-37) sequence, or an analogue or a functional derivative
of such a peptide to a patient in a regimen which additionally
comprises treatment with an oral hypoglycaemic agent.
[0018] In a first preferred embodiment, the present invention
relates to the use of GLP-1(7-36)amide for the preparation of a
medicament for use in the treatment of type 2 diabetes in a regimen
which additionally comprises treatment with an oral hypoglycaemic
agent.
[0019] In a further preferred embodiment, the present invention
relates to the use of GLP-1(7-37) for the preparation of a
medicament for use in the treatment of type 2 diabetes in a regimen
which additionally comprises treatment with an oral hypoglycaemic
agent.
[0020] In a further preferred embodiment, the present invention
relates to the use of an analogue of GLP-1(7-37) for the
preparation of a medicament for use in the treatment of type 2
diabetes in a regimen which additionally comprises treatment with
an oral hypoglycaemic agent.
[0021] In a further preferred embodiment, the present invention
relates to the use of a functional derivative of GLP-1(7-37) for
the preparation of a medicament for use in the treatment of type 2
diabetes in a regimen which additionally comprises treatment with
an oral hypoglycaemic agent.
[0022] In a further preferred embodiment, the present invention
relates to the use of GLP-1(7-37) or a fragment thereof or an
analogue or a functional derivative of any of these including
GLP-1(7-36)amide for the preparation of a medicament for use in the
treatment of type 2 diabetes in a regimen which additionally
comprises treatment with tolbutamide.
[0023] In a further preferred embodiment, the present invention
relates to the use of GLP-1(7-37) or a fragment thereof or an
analogue or a functional derivative of any of these including
GLP-1(7-36)amide for the preparation of a medicament for use in the
treatment of type 2 diabetes in a regimen which additionally
comprises treatment with glibenclamide.
[0024] In a further preferred embodiment, the present invention
relates to the use of GLP-1(7-37) or a fragment thereof or an
analogue or a functional derivative of any of these including
GLP-1(7-36)amide for the preparation of a medicament for use in the
treatment of type 2 diabetes in a regimen which additionally
comprises treatment with glipizide.
[0025] In a further preferred embodiment, the present invention
relates to the use of GLP-1(7-37) or a fragment thereof or an
analogue or a functional derivative of any of these including
GLP-1(7-36)amide for the preparation of a medicament for use in the
treatment of type 2 diabetes in a regimen which additionally
comprises treatment with gliclazide.
[0026] In a further preferred embodiment, the present invention
relates to the use of GLP-1(7-37) or a fragment thereof or an
analogue or a functional derivative of any of these including
GLP-1(7-36)amide for the preparation of a medicament for use in the
treatment of type 2 diabetes in a regimen which additionally
comprises treatment with a biguanide.
[0027] In a further preferred embodiment, the present invention
relates to the use of GLP-1(7-37) or a fragment thereof or an
analogue or a functional derivative of any of these including
GLP-1(7-36)amide for the preparation of a medicament for use in the
treatment of type 2 diabetes in a regimen which additionally
comprises treatment with metformin.
[0028] In a further preferred embodiment, the present invention
relates to the use of GLP-1(7-37) or a fragment thereof or an
analogue or a functional derivative of any of these including
GLP-1(7-36)amide for the preparation of a medicament for use in the
treatment of type 2 diabetes in a regimen which additionally
comprises treatment with
(S)-(+)-2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]-amino]-
-2-oxoethyl]benzoic acid.
[0029] In this specification, analogues of GLP-1(7-37) or of
GLP-1(7-36)amide, respectively, means peptides which differ from
GLP-1(7-37) or from GLP-1(7-36)amide, respectively, in that at
least one of the amino acid residues of GLP-1(7-37) or of
GLP-1(7-36)amide, respectively, independently has been exchanged by
another amino acid residue, preferably one which can be coded for
by the genetic code. The definition also comprises the case when
amino acid residues are added at or deleted from the N-terminal
and/or the C-terminal end of the peptide. Preferably, the total
number of such additions, deletions and exchanges does not exceed
five, more preferred it does not exceed three.
DETAILED DESCRIPTION OF THE INVENTION
[0030] As mentioned above, patients treated with sulfonylureas
gradually fail to respond to sulfonylurea treatment. It is
generally accepted among those skilled in the art that this failure
is due to exhaustion of .beta.-cells which, accordingly, are unable
to excrete insulin in response to glucose stimulation. Also, it is
generally accepted that the efficacy of sulfonylureas is limited by
the capacity of .beta.-cells to produce and excrete insulin.
Accordingly, one would not expect any additional therapeutic
advantage by treating NIDDM patients with sulfonylureas and other
agents stimulating .beta.-cell function as well.
[0031] Our finding that NIDDM patients may advantageously be
treated with GLP-1 related peptides in combination with
sulfonylureas or other oral hypoglycaemic agents is therefore,
indeed, surprising. In fact, we have found that concomitant
treatment with oral hypoglycaemic agents and GLP-1 related peptides
results in a synergistic response by the NIDDM patients: treatment
with oral hypoglycaemic agents and GLP-1 related peptides gives
rise to a metabolic response greater than the sum of the responses
of either agents when applied alone. Even in cases of sulfonylurea
failures, the oral agents have been found to significantly enhance
efficacy of GLP-1 related peptides.
[0032] Combined treatment with GLP-1 related peptides and oral
hypoglycaemic agents is thus novel, therapeutically useful, and
surprising. Unforeseen, therapeutic advantages can be gained by
treating the NIDDM patients with both types of drugs.
[0033] Among the GLP-1 related peptides that can thus be used in
the treatment of type 2 diabetes GLP-1(7-37) and GLP-1(7-36)amide
are particularly advantageous, as they are identical to the
naturally occurring hormones. Shorter peptides comprising part of
the GLP-1(7-37) sequence or analogues of such shorter peptides or
analogues of GLP-1(7-37) itself or functional derivatives of any of
these can also be used to advantage, since pharmacodynamic and
pharmacokinetic properties can be changed according to patients'
demand by modifying the GLP-1 related fragment.
[0034] The GLP-1 related peptides can be administered by methods
currently available according to the invention for administration
of peptides. Nasal application is particularly advantageous from a
patient complience point of view. Details in this respect can be
found in our copending Danish patent application No. DK 0364/92
relating to nasal administration of medicaments comprising GLP-1
related peptides which was filed simultaneously with the present
application. The contents of said application is hereby
incorporated in its entirety by reference. Administration by
injection or infusion will be preferred in instances where a
specific protracted plasma profile of the active peptide is
required, and oral administration is preferred in instances where
extent and kinetics of absorption is not a critical issue.
[0035] The oral hypoglycaemic agent used according to the invention
can be any oral agent exhibiting a glucose lowering effect. Among
these agents, those acting on the ATP-dependent potassium channel
of the .beta.-cells are preferred such as glibenclamide, glipizide,
gliclazide and AG-EE 623 ZW. The peptides according to the
invention may also advantageously be applied in combination with
other oral agents such as metformin and related compounds or
glucosidase inhibitors as, for example, acarbose.
[0036] The features disclosed in the present description, examples
and claims may, both separately and in any combination thereof, be
material for realizing this invention in diverse forms thereof. The
invention is further illustrated by the following examples which
are not to be construed as limiting, but merely as an illustration
of some preferred features of the invention.
EXAMPLE 1
Synergistic Effect of GLP-1(7-36)amide and Glibenclamide in NIDDM
Patients.
Assays
[0037] Blood samples were collected in plastic tubes containing
EDTA (0.048 ml, 0.34 M) and Trasylol.RTM. (1000 IU Kallikrein
inhibitor, obtained from Bayer, West Germany) and immediately
placed on ice. The samples were centrifuged at 4.degree. C. and the
plasma was stored at -20.degree. C. Blood glucose was measured by a
glucose oxidase method according to A. S. Hugget and D. A. Nixon,
Lancet 2 (1957) 368-370. Plasma C-peptide concentrations were
determined by radioimmunoassay (RIA) using a commercially available
kit (Novo Research Institute, Denmark). Plasma glucagon
concentrations were measured by RIA using antibody 30K as described
by G. R. Faloona and R. H. Unger in B. M. Jaffe and Behrman, eds.
Methods of Hormone Radioimmunoassay, Academic Press, New York
(1974) 317-330.
[0038] For further experimental details (e.g. on calculation of
isoglycaemic meal-related insulin response, IMIR), reference is
made to M. Gutniak, C. Orskov, J. J. Holst, B. Ahren and S.
efendic, The New England Journal of Medicine 326 (29) (1992)
1316-1322, where a different experiment performed under similar
conditions is described.
Methods
[0039] On four different days the effect of either injecting
glibenclamide, 1 mg i.v., or infusing GLP-1(7-36)amide at a rate of
0.75 pmol per kilogram of body weight per minute or a combination
thereof was studied in the same group of 6 insulin treated obese
NIDDM patients (Body Mass Index: 30.1.+-.2.4 kg/m.sup.2) and
compared to administration of saline as control. Ordinary
administration of insulin was stopped 24 hours before the
administration of the test compounds or of the saline started and
all subjects were fasted overnight. A Biostator (Miles, Diagnostic
Division, Elkhart, Ind.) was used for insulin administration in
this period in order to normalize blood glucose levels before the
administration of the test compounds was initiated and also to keep
a normal postprandial blood glucose pattern 180 minutes following
the ingestion of a standard test meal comprising boiled potatoes,
boiled beef, cooked carrots, a glass of milk containing 0.5%
butterfat, and a slice of bread baked from a mixture of wheat and
rye flours. In this meal, 28, 26, and 46% of the energy comes from
protein, fat and carbohydrates, respectively. Administration of the
test compounds was performed (glibenclamide, saline) or initiated
(GLP-1(7-36)amide, respectively, 30 minutes after normoglycaemia
was achieved. The infusion of (GLP-1(7-36)amide was continued for
210 minutes. After 30 minutes (time zero), the subjects were given
the test meal which was consumed within 15 minutes. Blood samples
were obtained at -30, 0, 15, 30, 90, 120, 150 and 180 minutes.
Results
[0040] After the ingestion of the meal, meal-related C-peptide
response, glucagon response and isoglycaemic meal-related insulin
requirement (IMIR) was measured. The results are summerized in
Table 1. TABLE-US-00002 TABLE 1 C-peptide response Glucagon
(pg/ml/210 response min) (pg/ml/210 min) IMIR (U) Control (saline)
7.4 .+-. 3.6 269345 .+-. 6299 17.4 .+-. 2.8 GLP-1(7-36)amide 25
.+-. 9.8 10451 .+-. 5126 6.3 .+-. 2.0 glibenclamide 105 .+-. 53.9
*) 8.3 .+-. 1.0 GLP-1(7-36)amide + 184 .+-. 55.1 2526 .+-. 4873 2.7
.+-. 0.7 glibenclamide *) glibenclamide had no significant
influence on glucagon release.
[0041] As indicated in the table, both GLP-1(7-36)amide and
glibenclamide significantly increased meal-related C-peptide
response (p<0.02) and when administered in combination exerted a
clear synergistic effect. GLP-1(7-36)amide suppressed the glucagon
response (p<0.01) while glibenclamide had no significant effect.
However, in combination with GLP-1(7-36)amide the glucagon response
was almost abolished. Finally, both glibenclamide and
GLP-1(7-36)amide lowered IMIR and in combination IMIR was as low as
2.7.+-.0.7.
[0042] In summary, this experiment demonstrates a strong
synergistic effect of a combination of GLP-1(7-36)amide and
glibenclamide.
EXAMPLE 2
Synergistic Effect of GLP-1(7-36)amide and Glibenclamide in NIDDM
Patients With Secondary Failure to Sulfonylurea Treatment.
Methods.
[0043] Eight patients with NIDDM and secondary failure to
sulfonylurea treatment participated in the study (age 57.6.+-.2.7
years, body mass index 28.7.+-.1.5 kg/m.sup.2, diabetes duration
7.6.+-.1.2 years, HbA.sub.1C 5.8.+-.0.5). The diabetic patients
fulfilled the criteria for NIDDM and IDDM according to the USA
National Diabetes Data Group. None of the patients had impaired
renal function, automatic neuropathy, or proliferative retinopathy,
and all had normal liver function. They were instructed to eat a
standard diet for diabetic patients at least 2 weeks before and
during the study. The patients treated with sulfonylureas stopped
their medication one week before the experiments. Those who were
treated with insulin were instructed to stop the injections of NPH
insulin 24 hours before the studies. Blood glucose concentrations
were controlled with subcutaneous injections of regular
insulin.
[0044] All the subjects were studied after an overnight fast. At
07.30 h on the morning of each study, three cannulas were inserted.
One cannula was placed in an antecubital vein and was used to
sample blood intermittently for hormone assays. It was flushed with
saline after each sampling. A second cannula inserted retro-gradely
in a dorsal hand vein was used for continuous monitoring of blood
glucose concentrations. The venous blood was arterialized by
heating the forearm and hand in a thermoregulated sleeve (Kanthal
Medical Heating AB, Stockholm, Sweden) at 45.degree. C . The third
cannula was inserted in the contralateral antecubital vein and was
used for all infusions. From approximately 08.00 hours, the
patients were connected to a Biostator in order to normalize their
blood glucose concentrations. The algorithm of the Biostator was
adjusted in order to normalize basal blood glucose levels. The
target for blood glucose concentrations was 4-5 mmol/L. When the
target was reached, the Biostator algorithm was changed to
monitoring and the feedback insulin infusion was stopped. The
experiments were started 30 minutes after normoglycemia was
achieved, approximately 90 minutes after connection to the
Biostator. An infusion of saline or 0.75 pmol/kg/min of
GLP-1(7-36)amide (Peninsula Laboratories, St. Helens, Merseyside,
England) then was started and continued for 210 minutes. In
glibenclamide experiments an i.v. injection of 1 mg glibenclamide
(Hoechst AG, Germany) was given at the same time point. These four
studies were performed in a random order with 2-4 weeks elapsed
between the experiments. At time 0 the subjects were given a
standard lunch, as described in Example 1 which they ate within 15
minutes while sitting in bed. Blood samples were taken at FV, -60,
-30, -15, 0, 15, 30, 90, 120, 150, and 180 minutes. Blood glucose
was measured continuously.
Results.
[0045] In the basal state, the effect on blood glucose and
C-peptide levels was monitored 45 minutes after administration of
GLP-1(7-36)amide, glibenclamide or a combination thereof had
started. The results are summarized in Table 2. TABLE-US-00003
TABLE 2 Blood glucose C-peptide mmol/l pmol/l Control (saline) 6.0
.+-. 0.3 0.53 .+-. 0.06 GLP-1(7-36)amide 5.1 .+-. 0.4 0.63 .+-. 0.1
glibenclamide 6.0 .+-. 0.3 0.56 .+-. 0.007 GLP-1(7-36)amide + 4.5
.+-. 0.1 0.72 .+-. 0.1 glibenclamide
[0046] These results clearly demonstrates the synergistic effect of
the two compounds as glibenclamide had no significant effect on its
own while the effect of the combination of GLP-1(7-36)amide and
glibenclamide, clearely, exeeded that of GLP-1(7-36)amide
alone.
[0047] After the ingestion of the meal, the insulinogenic indices
(integrated insulin/integrated glucose response) were calculated,
again highlighting the synergistic effect of the two compounds, a
shown in Table 3. TABLE-US-00004 TABLE 3 Insulinogenic index
Control (saline) 1.6 .+-. 0.6 GLP-1(7-36)amide 21.0 .+-. 7.2,
glibenclamide 10.6 .+-. 2.8, GLP-1(7-36)amide + glibenclamide 37.5
.+-. 9
[0048]
Sequence CWU 1
1
1 1 31 PRT Homo sapiens VARIANT (1)..(31) Xaa = Gly or no amino
acid 1 His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu
Gly 1 5 10 15 Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly
Arg Xaa 20 25 30
* * * * *